The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients

References

• MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Cause Contr 2006;17:989–1003
   PubMed Web of Science ®Google Scholar
• Strom SS, Wang X, Pettaway CA, et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 2005;11:6889–94
   PubMed Web of Science ®Google Scholar
• Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066–73
   PubMed Web of Science ®Google Scholar
• Hanks GE, Pajak TF, Porter A, et al; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972–8
   PubMed Web of Science ®Google Scholar
• Warde P, Mason M, Ding K, et al.; NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378:2104–11
   PubMed Web of Science ®Google Scholar
• Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599–603
   PubMed Web of Science ®Google Scholar
• Berruti A, Dogliotti L, Terrone C, et al.; Gruppo Onco Urologico Piemontese (G.O.U.P.), Rete Oncologica Piemontese. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167:2361–7
   PubMed Web of Science ®Google Scholar
• Braunstein LZ, Chen MH, Loffredo M, et al. Obesity and the odds of weight gain following androgen deprivation therapy for prostate cancer. Prostate Cancer 2014;2014:230812
   Google Scholar
• Inaba M, Otani Y, Nishimura K, et al. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism 2005;54:55–9
   PubMedGoogle Scholar
• Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24:3979–83
   PubMed Web of Science ®Google Scholar
• Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 2008;28:1511–22
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr Pharm Des 2010;16:1896–901
   PubMed Web of Science ®Google Scholar
• Maeda K. Role of adiponectin and adipocyte fatty acid binding protein in the metabolic syndrome. Diabetes Res Clin Pract 2007;77:S17–22
   Google Scholar
• Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002;51:2734–41
   PubMed Web of Science ®Google Scholar
• Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008;71:318–22
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008;7:489–503
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008;77:289–312
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996;274:1377–9
   PubMed Web of Science ®Google Scholar
• Tso AW, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007;30:2667–72
   PubMed Web of Science ®Google Scholar
• Makowski L, Boord JB, Maeda K, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001;7:699–705
   PubMed Web of Science ®Google Scholar
• Boord JB, Maeda K, Makowski L, et al. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002;22:1686–91
   PubMed Web of Science ®Google Scholar
• Boord JB, Maeda K, Makowski L, et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004;110:1492–8
   PubMed Web of Science ®Google Scholar
• Gupta V, Bhasin S, Guo W, et al. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol 2008;296:32–40
   PubMed Web of Science ®Google Scholar
• Lai JJ, Lai KP, Chuang KH, et al. Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest 2009;119:3739–51
   PubMed Web of Science ®Google Scholar
• Rettew JA, Huet-Hudson YM, Marriott I. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biol Reprod 2008;78:432–7
   PubMed Web of Science ®Google Scholar
• Elmasri H, Karaaslan C, Teper Y, et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009;23:3865–73
   PubMed Web of Science ®Google Scholar
• Elmasri H, Ghelfi E, Yu CW, et al. Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis 2012;15:457–68
   PubMedGoogle Scholar
• Iso T, Maeda K, Hanaoka H, et al. Capillary endothelial fatty acid binding proteins 4 and 5 play a critical role in fatty acid uptake in heart and skeletal muscle. Arterioscler Thromb Vasc Biol 2013;33:2549–57
   PubMed Web of Science ®Google Scholar
• Torres-Estay V, Carreno D, San Francisco IF, et al. Androgen receptor in human endothelial cells. J Endocrinol 2015;224:R131–7
   PubMed Web of Science ®Google Scholar
• Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab 2014;28:119–30
   Google Scholar
• Aronson WJ, Glaspy JA, Reddy ST, et al. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology 2001;58:283–8
   PubMed Web of Science ®Google Scholar
• Hoenjet KM, Dagnelie PC, Delaere KP, et al. Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study. Eur Urol 2005;47:433–9
   Google Scholar
• Kucuk O, Sarkar FH, Djuric Z, et al. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood) 2002;227:881–5
   PubMed Web of Science ®Google Scholar
• Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Nat Cancer Inst 1998;90:440–6
   PubMed Web of Science ®Google Scholar
• Hussain M, Banerjee M, Sarkar FH, et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2003;47:111–17
   PubMed Web of Science ®Google Scholar